UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
FDA approval of ZILBRYSQ® has been granted for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody-positive1ZILBRYSQ is the first...